NovoCure Limited (NVCR) Return on equity 2017–2026
NovoCure Limited (NVCR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-40.0%FY2026 · since FY2017: -92.6% → -40.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -40.0% | +6.8 pp |
| FY2025 | -46.8% | +10.3 pp |
| FY2024 | -57.1% | -36.1 pp |
| FY2023 | -21.0% | -6.8 pp |
| FY2022 | -14.2% | -18.4 pp |
| FY2021 | 4.2% | +7.5 pp |
| FY2020 | -3.3% | +53.3 pp |
| FY2019 | -56.6% | -2.3 pp |
| FY2018 | -54.3% | +38.3 pp |
| FY2017 | -92.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More NVCR financial trends
NVCR RevenueNVCR Net incomeNVCR Net marginNVCR Gross profitNVCR Gross marginNVCR Operating incomeNVCR Operating marginNVCR Operating cash flowNVCR Free cash flowNVCR Capital expendituresNVCR Stock buybacksNVCR Dividends paidNVCR Total assetsNVCR Total liabilitiesNVCR Shareholders’ equityNVCR overview →